

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5973597

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BERNARD CHARLES SHERMAN, DECEASED, BY JACK M. KAY, TRUSTEE FOR THE ESTATE OF BERNARD CHARLES SHERMAN	10/23/2018
MICHAEL SPINO	10/23/2018
RECEIVING PARTY DATA	
Name:	APOTEX INC.
Street Address:	150 SIGNET DRIVE
City:	TORONTO, ONTARIO
State/Country:	CANADA
Postal Code:	M9L1T9
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16714520
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202-371-2600
Email:	BNCOMBS@sternekessler.com, jmccoy@sternekessler.com, ttopssecretary2@sternekessler.com, jyando@sternekessler.com
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
Address Line 1:	1100 NEW YORK AVENUE NW
Address Line 4:	WASHINGTON, D.C. 20005
ATTORNEY DOCKET NUMBER:	4559.0090005
NAME OF SUBMITTER:	BONNIE W. NANNENGA-COMBS, REG. NO. 67836
SIGNATURE:	/Bonnie W. Nannenga-Combs/
DATE SIGNED:	02/20/2020
Total Attachments: 3	
source=2020-02-20-Assignment-Inventors-Apotex-4559-0090005#page1.tif	
source=2020-02-20-Assignment-Inventors-Apotex-4559-0090005#page2.tif	
source=2020-02-20-Assignment-Inventors-Apotex-4559-0090005#page3.tif	

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Bernard Charles SHERMAN** (deceased, undersigned by legal representative) and **Michael SPINO**, hereby sell and assign to **Apotex Inc.**, a corporation formed under the laws of Canada, whose mailing address is 150 Signet Drive, Toronto, Ontario M9L1T9 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAME** for which provisional applications for patent in the United States of America were filed on October 25, 2017 (also known as United States Application No. 62/577,055) and December 7, 2017 (also known as United States Application No. 62/596,043), in any and all non-provisional applications therefrom, in any and all Letters Patent(s) granted from such non-provisional applications, and

(b) in any and all applications that claim the benefit of the patent application(s) listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventor or legal representative had this assignment and sale not been made.

The undersigned inventor and legal representative agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s)

thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventor and legal representative agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventor and legal representative hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventor and legal representative hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventor and legal representative hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are NOT the legal representatives of, and attorneys for, the inventors or legal representative.

IN WITNESS WHEREOF, executed by the undersigned inventor and legal representative on the date opposite his/her name.


Date: Oct. 23, 2018

Signature of Legal Representative of Inventor:


Legal Representative of
Bernard Charles SHERMAN


Date: Oct. 23, 2018

Signature of Inventor:


Michael SPINO

SIGNED on behalf of the said ASSIGNEE,

APOTEX INC.

By:  _____

Name: Kevin Mark Zive _____

Title: VP, Global Intellectual Property _____

Date: 10/23/2018 _____

9852370_2.docx